Literature DB >> 11943705

Heterogeneous methylation and deletion patterns of the INK4a/ARF locus within prostate carcinomas.

Noboru Konishi1, Mitsutoshi Nakamura, Munehiro Kishi, Masayoshi Nishimine, Eiwa Ishida, Keiji Shimada.   

Abstract

To elucidate the role of p53/p16(INK4a)/RB1 pathways in prostate carcinogenesis, we analyzed the p14(ARF), p16(INK4a), RB1, p21(Waf1), p27(Kip1), PTEN, p73, p53, and MDM2 gene status of multiple areas within 16 histologically heterogeneous prostate carcinomas using methylation-specific polymerase chain reaction, differential polymerase chain reaction, and immunohistochemistry. All focal areas examined had Gleason scores ranging from 1 to 5. Methylation of either PTEN or p73 was undetected in any sample, whereas expression of MDM2 seemed to be an independent event within small foci of 4 of 16 tumors. Loss of p14(ARF), p16(INK4a), RB1, and p27(Kip1) expression correlated with homozygous deletion or promoter hypermethylation. One carcinoma showed co-deletion of both p14(ARF) and p16(INK4a) in two of five areas examined; two areas within another tumor demonstrated concurrent hypermethylation of the promoter regions of the same genes. Focal hypermethylation of RB1, p21(Waf1), and p27(Kip1) was detected within two, two, and three tumors, respectively. These findings indicate that both genetic and epigenetic events occur independently in intratumor foci and further suggest hypermethylation-induced loss of gene function may be as critical as specific genetic mutations in prostate carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11943705      PMCID: PMC1867197          DOI: 10.1016/S0002-9440(10)62547-3

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  40 in total

1.  Aberrations of the p53 pathway components p53, MDM2 and CDKN2A appear independent in diffuse large B cell lymphoma.

Authors:  M B Møller; Y Ino; A M Gerdes; K Skjødt; D N Louis; N T Pedersen
Journal:  Leukemia       Date:  1999-03       Impact factor: 11.528

2.  Prognostic value and expression of p21(waf1/cip1) protein in prostate cancer.

Authors:  S Aaltomaa; P Lipponen; M Eskelinen; M Ala-Opas; V M Kosma
Journal:  Prostate       Date:  1999-04-01       Impact factor: 4.104

3.  Translational control of p27Kip1 accumulation during the cell cycle.

Authors:  L Hengst; S I Reed
Journal:  Science       Date:  1996-03-29       Impact factor: 47.728

4.  Frequent alterations of the p14(ARF) and p16(INK4a) genes in primary central nervous system lymphomas.

Authors:  M Nakamura; T Sakaki; H Hashimoto; H Nakase; E Ishida; K Shimada; N Konishi
Journal:  Cancer Res       Date:  2001-09-01       Impact factor: 12.701

5.  Genetic changes in prostate cancer.

Authors:  N Konishi; M Cho; K Yamamoto; Y Hiasa
Journal:  Pathol Int       Date:  1997-11       Impact factor: 2.534

6.  Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5' CpG island methylation.

Authors:  P G Corn; S J Kuerbitz; M M van Noesel; M Esteller; N Compitello; S B Baylin; J G Herman
Journal:  Cancer Res       Date:  1999-07-15       Impact factor: 12.701

7.  ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways.

Authors:  Y Zhang; Y Xiong; W G Yarbrough
Journal:  Cell       Date:  1998-03-20       Impact factor: 41.582

8.  The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53.

Authors:  J Pomerantz; N Schreiber-Agus; N J Liégeois; A Silverman; L Alland; L Chin; J Potes; K Chen; I Orlow; H W Lee; C Cordon-Cardo; R A DePinho
Journal:  Cell       Date:  1998-03-20       Impact factor: 41.582

9.  Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2.

Authors:  T Kamijo; J D Weber; G Zambetti; F Zindy; M F Roussel; C J Sherr
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-07       Impact factor: 11.205

10.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.

Authors:  J G Herman; J R Graff; S Myöhänen; B D Nelkin; S B Baylin
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

View more
  28 in total

1.  Heterogeneity of DNA methylation in multifocal prostate cancer.

Authors:  Inga Serenaite; Kristina Daniunaite; Feliksas Jankevicius; Arvydas Laurinavicius; Donatas Petroska; Juozas R Lazutka; Sonata Jarmalaite
Journal:  Virchows Arch       Date:  2014-11-05       Impact factor: 4.064

2.  Qualitative and quantitative promoter hypermethylation patterns of the P16, TSHR, RASSF1A and RARβ2 genes in papillary thyroid carcinoma.

Authors:  Javad Mohammadi-asl; Bagher Larijani; Zhamak Khorgami; Seyed Mohammad Tavangar; Vahid Haghpanah; Majid Kheirollahi; Parvin Mehdipour
Journal:  Med Oncol       Date:  2010-06-10       Impact factor: 3.064

Review 3.  Promoter hypermethylation in prostate cancer.

Authors:  Jong Y Park
Journal:  Cancer Control       Date:  2010-10       Impact factor: 3.302

Review 4.  Radiosensitization of prostate cancer by priming the wild-type p53-dependent cellular senescence pathway.

Authors:  Brian D Lehmann; James A McCubrey; David M Terrian
Journal:  Cancer Biol Ther       Date:  2007-08-05       Impact factor: 4.742

5.  Critical and distinct roles of p16 and telomerase in regulating the proliferative life span of normal human prostate epithelial progenitor cells.

Authors:  Bobby Bhatia; Ming Jiang; Mahipal Suraneni; Lubna Patrawala; Mark Badeaux; Robin Schneider-Broussard; Asha S Multani; Collene R Jeter; Tammy Calhoun-Davis; Limei Hu; Jianhua Hu; Spiridon Tsavachidis; Wei Zhang; Sandy Chang; Simon W Hayward; Dean G Tang
Journal:  J Biol Chem       Date:  2008-07-28       Impact factor: 5.157

Review 6.  Mechanisms of environmental chemicals that enable the cancer hallmark of evasion of growth suppression.

Authors:  Rita Nahta; Fahd Al-Mulla; Rabeah Al-Temaimi; Amedeo Amedei; Rafaela Andrade-Vieira; Sarah N Bay; Dustin G Brown; Gloria M Calaf; Robert C Castellino; Karine A Cohen-Solal; Annamaria Colacci; Nichola Cruickshanks; Paul Dent; Riccardo Di Fiore; Stefano Forte; Gary S Goldberg; Roslida A Hamid; Harini Krishnan; Dale W Laird; Ahmed Lasfar; Paola A Marignani; Lorenzo Memeo; Chiara Mondello; Christian C Naus; Richard Ponce-Cusi; Jayadev Raju; Debasish Roy; Rabindra Roy; Elizabeth P Ryan; Hosni K Salem; A Ivana Scovassi; Neetu Singh; Monica Vaccari; Renza Vento; Jan Vondráček; Mark Wade; Jordan Woodrick; William H Bisson
Journal:  Carcinogenesis       Date:  2015-06       Impact factor: 4.944

7.  Global methylation pattern of genes in androgen-sensitive and androgen-independent prostate cancer cells.

Authors:  Dhruva Kumar Mishra; Zujian Chen; Yanyuan Wu; Marianna Sarkissyan; H Phillip Koeffler; Jaydutt V Vadgama
Journal:  Mol Cancer Ther       Date:  2010-01-06       Impact factor: 6.261

8.  Integrated analysis of the genomic instability of PTEN in clinically insignificant and significant prostate cancer.

Authors:  Stephen J Murphy; Robert J Karnes; Farhad Kosari; B Edgardo R Parilla Castellar; Benjamin R Kipp; Sarah H Johnson; Simone Terra; Faye R Harris; Geoffrey C Halling; Janet L Schaefer Klein; Aqsa Nasir; Eric Bergstrahl; Laureano J Rangel; William R Sukov; George Vasmatzis; John C Cheville
Journal:  Mod Pathol       Date:  2015-11-27       Impact factor: 7.842

9.  Homozygous deletions and recurrent amplifications implicate new genes involved in prostate cancer.

Authors:  Wennuan Liu; Chunmei Carol Xie; Yi Zhu; Tao Li; Jishan Sun; Yu Cheng; Charles M Ewing; Sue Dalrymple; Aubrey R Turner; Jielin Sun; John T Isaacs; Bao-Li Chang; Siqun Lilly Zheng; William B Isaacs; Jianfeng Xu
Journal:  Neoplasia       Date:  2008-08       Impact factor: 5.715

10.  PTEN deficiency mediates a reciprocal response to IGFI and mTOR inhibition.

Authors:  Mukund Patel; Nicholas C Gomez; Andrew W McFadden; Billie M Moats-Staats; Sam Wu; Andres Rojas; Travis Sapp; Jeremy M Simon; Scott V Smith; Kathleen Kaiser-Rogers; Ian J Davis
Journal:  Mol Cancer Res       Date:  2014-07-03       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.